Pacira price target raised to $48 from $39 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Pacira (PCRX) to $48 from $39 and keeps a Buy rating on the shares. Pacira’s 2025 revenue guidance “looks almost unreasonably conservative,” the analyst tells investors in a research note. The firm sees the Exparel No Pain ramp beating guidance and a “major disconnect” in the shares despite the recent rebound.